| Company Name: |
Bide Pharmatech Ltd.
|
| Tel: |
400-164-7117 13681763483 |
| Email: |
product02@bidepharm.com |
| Products Intro: |
Product Name:2,5,8,11,14,17,20,23,26-Nonaoxanonacosan-29-oic acid
CAS:2576495-35-5
Purity:95% Package:250mg;1g;5g; Remarks:BD00836644
|
| Company Name: |
Amatek Scientific Co. Ltd.
|
| Tel: |
0512-56316828 |
| Email: |
info@amateksci.com |
| Products Intro: |
Product Name:mPEG8-CH2CH2COOH
CAS:2576495-35-5
Purity:97% HPLC Package:1g;5g;25g;100g
|
| Company Name: |
Xi'an Confluore Biological Technology Co., Ltd.
|
| Tel: |
+86-156-80926068 +86-15680926068 |
| Email: |
1924344760@qq.com |
| Products Intro: |
Product Name:m-PEG9-COOH
CAS:2576495-35-5
Purity:98% HPLC Package:10MG;25MG;50MG;100MG;1G;5G Remarks:For customers outside China,please use the website:www.confluore.com
|
m-PEG9-COOH manufacturers
- m-PEG9-COOH
-
- $0.00 / 5g
-
2024-03-27
- CAS:2576495-35-5
- Min. Order: 5g
- Purity: >98.00%
- Supply Ability: 5g
|
| | m-PEG9-COOH Basic information |
| Product Name: | m-PEG9-COOH | | Synonyms: | m-PEG9-COOH;2,5,8,11,14,17,20,23,26-Nonaoxanonacosan-29-oic acid;4,7,10,13,16,19,22,25,28-Nonaoxanonacosanoic acid;mPEG8-CH2CH2COOH/4,7,10,13,16,19,22,25,28-Nonaoxanonacosanoic acid;3-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoic acid | | CAS: | 2576495-35-5 | | MF: | C20H40O11 | | MW: | 456.52 | | EINECS: | | | Product Categories: | | | Mol File: | 2576495-35-5.mol |  |
| | m-PEG9-COOH Chemical Properties |
| Boiling point | 536.3±50.0 °C(Predicted) | | density | 1.111±0.06 g/cm3(Predicted) | | pka | 4.28±0.10(Predicted) | | form | Liquid | | color | Colorless to light yellow |
| | m-PEG9-COOH Usage And Synthesis |
| Biological Activity | m-PEG9-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs[1].
PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[1]. | | References | [1]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562 |
| | m-PEG9-COOH Preparation Products And Raw materials |
|